Analysts at StockNews.com began coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Rating) in a research note issued on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
Regulus Therapeutics Price Performance
NASDAQ RGLS opened at $1.26 on Monday. The firm has a market cap of $18.43 million, a P/E ratio of -0.57 and a beta of 1.65. The stock’s 50-day moving average is $1.43 and its 200-day moving average is $1.55. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.70.
Institutional Investors Weigh In On Regulus Therapeutics
A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. lifted its stake in Regulus Therapeutics by 108.5% in the 3rd quarter. BlackRock Inc. now owns 45,614 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 23,738 shares in the last quarter. Commonwealth Equity Services LLC grew its position in Regulus Therapeutics by 52.3% in the third quarter. Commonwealth Equity Services LLC now owns 33,500 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 11,500 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in Regulus Therapeutics in the 3rd quarter valued at $54,000. Renaissance Technologies LLC lifted its position in Regulus Therapeutics by 498.2% during the 1st quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 111,100 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Regulus Therapeutics by 42.9% in the 1st quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 50,518 shares in the last quarter. Institutional investors and hedge funds own 55.47% of the company’s stock.
Regulus Therapeutics Company Profile
Regulus Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
- Get a free copy of the StockNews.com research report on Regulus Therapeutics (RGLS)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.